These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 33835019)

  • 21. The role of the complement system and the activation fragment C5a in the central nervous system.
    Woodruff TM; Ager RR; Tenner AJ; Noakes PG; Taylor SM
    Neuromolecular Med; 2010 Jun; 12(2):179-92. PubMed ID: 19763906
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The cytokine storm-An appropriate, over-reactive response to SARS-CoV-2 or the wrong immune pathway?
    Bellgrau D; Modiano JF
    Scand J Immunol; 2021 Mar; 93(3):e12979. PubMed ID: 32991014
    [No Abstract]   [Full Text] [Related]  

  • 23. Des-Arg9 bradykinin and bradykinin potentially trigger cytokine storm in patients with COVID-19.
    Alikhani M; Javadi A; Aalikhani M
    Iran J Immunol; 2021 Mar; 18(1):93-94. PubMed ID: 33787518
    [No Abstract]   [Full Text] [Related]  

  • 24. Complement drives glucosylceramide accumulation and tissue inflammation in Gaucher disease.
    Pandey MK; Burrow TA; Rani R; Martin LJ; Witte D; Setchell KD; Mckay MA; Magnusen AF; Zhang W; Liou B; Köhl J; Grabowski GA
    Nature; 2017 Mar; 543(7643):108-112. PubMed ID: 28225753
    [TBL] [Abstract][Full Text] [Related]  

  • 25. What triggers severe COVID? Infected immune cells hold clues.
    Mallapaty S
    Nature; 2022 Apr; 604(7905):231. PubMed ID: 35388153
    [No Abstract]   [Full Text] [Related]  

  • 26. Cytokine Storm: The Primary Determinant for the Pathophysiological Evolution of COVID-19 Deterioration.
    Chen R; Lan Z; Ye J; Pang L; Liu Y; Wu W; Qin X; Guo Y; Zhang P
    Front Immunol; 2021; 12():589095. PubMed ID: 33995341
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pharmacological approach for the reduction of inflammatory and prothrombotic hyperactive state in COVID-19 positive patients by acting on complement cascade.
    Vitiello A; La Porta R; D'Aiuto V; Ferrara F
    Hum Immunol; 2021 Apr; 82(4):264-269. PubMed ID: 33632561
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Can Natural Killer Cells Be a Principal Player in Anti-SARS-CoV-2 Immunity?
    Ahmed F; Jo DH; Lee SH
    Front Immunol; 2020; 11():586765. PubMed ID: 33365027
    [No Abstract]   [Full Text] [Related]  

  • 29. Targeting the Complement-Sphingolipid System in COVID-19 and Gaucher Diseases: Evidence for a New Treatment Strategy.
    Trivedi VS; Magnusen AF; Rani R; Marsili L; Slavotinek AM; Prows DR; Hopkin RJ; McKay MA; Pandey MK
    Int J Mol Sci; 2022 Nov; 23(22):. PubMed ID: 36430817
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The 49th Annual Meeting of the Japanese Society for Immunology: COVID-19 and Immunity.
    Shinkura R; Kang S; Arase H; Toyama-Sorimachi N
    Int Immunol; 2021 Mar; 33(4):193-196. PubMed ID: 33538811
    [No Abstract]   [Full Text] [Related]  

  • 31. SARS-CoV-2 Antibodies Mediate Complement and Cellular Driven Inflammation.
    Jarlhelt I; Nielsen SK; Jahn CXH; Hansen CB; Pérez-Alós L; Rosbjerg A; Bayarri-Olmos R; Skjoedt MO; Garred P
    Front Immunol; 2021; 12():767981. PubMed ID: 34804055
    [TBL] [Abstract][Full Text] [Related]  

  • 32. C5a elevation in convalescents from severe COVID-19 is not associated with early complement activation markers C3bBbP or C4d.
    Kowalska D; Kuźniewska A; Senent Y; Tavira B; Inogés S; López-Díaz de Cerio A; Pio R; Okrój M; Yuste JR
    Front Immunol; 2022; 13():946522. PubMed ID: 36091057
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Complex immune deregulation in severe COVID-19: More than a mechanism of pathogenesis.
    Giamarellos-Bourboulis EJ
    EBioMedicine; 2021 Nov; 73():103673. PubMed ID: 34742130
    [No Abstract]   [Full Text] [Related]  

  • 34. The Outcome of Critically Ill COVID-19 Patients Is Linked to Thromboinflammation Dominated by the Kallikrein/Kinin System.
    Lipcsey M; Persson B; Eriksson O; Blom AM; Fromell K; Hultström M; Huber-Lang M; Ekdahl KN; Frithiof R; Nilsson B
    Front Immunol; 2021; 12():627579. PubMed ID: 33692801
    [TBL] [Abstract][Full Text] [Related]  

  • 35. COVID-19 Severity Is Associated with Differential Antibody Fc-Mediated Innate Immune Functions.
    Adeniji OS; Giron LB; Purwar M; Zilberstein NF; Kulkarni AJ; Shaikh MW; Balk RA; Moy JN; Forsyth CB; Liu Q; Dweep H; Kossenkov A; Weiner DB; Keshavarzian A; Landay A; Abdel-Mohsen M
    mBio; 2021 Apr; 12(2):. PubMed ID: 33879594
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Complement Activation in the Disease Course of Coronavirus Disease 2019 and Its Effects on Clinical Outcomes.
    de Nooijer AH; Grondman I; Janssen NAF; Netea MG; Willems L; van de Veerdonk FL; Giamarellos-Bourboulis EJ; Toonen EJM; Joosten LAB;
    J Infect Dis; 2021 Feb; 223(2):214-224. PubMed ID: 33038254
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Immune Responses to the Novel Coronavirus-2: Friend or Foe?
    Mahmoodpoor A; Nader ND
    Immunol Invest; 2021 Nov; 50(8):949-951. PubMed ID: 32689852
    [No Abstract]   [Full Text] [Related]  

  • 38. Immune response to COVID-19 infection: a double-edged sword.
    Saad N; Moussa S
    Immunol Med; 2021 Sep; 44(3):187-196. PubMed ID: 33444511
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Evolution Toward Severe Covid-19 From Biological Monitoring to Therapeutic Considerations.
    Carvelli J; Le Saux A; Bourenne J; Gainnier M; Kaplanski G
    Front Immunol; 2020; 11():562038. PubMed ID: 33384683
    [No Abstract]   [Full Text] [Related]  

  • 40. Targeting of the CD80/86 proinflammatory axis as a therapeutic strategy to prevent severe COVID-19.
    Julià A; Bonafonte-Pardàs I; Gómez A; López-Lasanta M; López-Corbeto M; Martínez-Mateu SH; Lladós J; Rodríguez-Nunez I; Myers RM; Marsal S
    Sci Rep; 2021 Jun; 11(1):11462. PubMed ID: 34075090
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.